A Comprehensive Update of Anti-COVID-19 Activity of Heterocyclic Compounds

References

• Satheesh D, Rajendran A, Chithra K. Protein-ligand binding interactions of imidazolium salts with SARS CoV-2. Heliyon. 2020;6(11):e05544. doi:10.1016/j.heliyon.2020.e05544
   PubMed Web of Science ®Google Scholar
• Astuti I. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metabolic Syndrome. 2020;14(4):407–412.
   PubMed Web of Science ®Google Scholar
• Verma VA, Saundane AR, Meti RS, Vennapu DR. Synthesis of novel indolo [3,2-c]isoquinoline derivatives bearing pyrimidine, piperazine rings and their biological evaluation and docking studies against COVID-19 virus main protease. J Mol Structures. 2021;1229:129829.
   PubMed Web of Science ®Google Scholar
• Murugavel S, Vasudevan P, Chandrasekaran R, Archana V, Ponnuswany A. Synthesis, crystal structure elucidation, DFT analysis, drug-likeness and ADMET evaluation and molecular docking studies of triazole derivatives: binary inhibition of spike protein and ACE2 receptor protein of COVID-19. J Chin Chem Soc. 2022;69(6):884–900.
   PubMed Web of Science ®Google Scholar
• Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al. Risk factors for COVID-19. Infez Med. 2020;28(4):469–474.
   PubMedGoogle Scholar
• Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy. Environ. Res. 2020;188:109819.
   PubMed Web of Science ®Google Scholar
• Nepolraj A, Shupeniuk VI, Sathiyaseelan M. Synthesis of new 3-(hydroxymethyl)-2-phenyl-2, 3 dihydroquinolinone and in-silico evaluation of COVID-19 main protease inhibitor. Vietnam J Chem. 2021;59(4):511–521.
   Google Scholar
• Holmes EC, Goldstein SA, Rasmussen AL, et al. The origins of SARS-CoV-2: a critical review. Cell. 2021;184(19):4848–4856.
   PubMed Web of Science ®Google Scholar
• Triggle CR, Bansal D, Ding H, et al. A comprehensive review of the viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. Front Immunol. 2021;12:631139.
   PubMed Web of Science ®Google Scholar
• Nizi MG, Persoons L, Corona A, et al. Discovery of 2-phenylquinolines with broad-spectrum anti-coronavirus activity. ACS Med Chem Lett. 2022;13(5):855–864.
   PubMed Web of Science ®Google Scholar
• Alotaibi SH, Amer HH, Touil N, Abdel-Moneim AS, Soliman MM, Zaki YH. Synthesis, characterization and molecular docking of new nucleosides and Schiff bases derived from ampyrone as antiviral agents to contain the COVID-19 virus. Polycyclic Aromatic Compounds. 2023;43(3):2418–2429.
   Web of Science ®Google Scholar
• Abu-Zaied MA, Elgemeie GH, Mahmoud NM. Anti-covid-19 drug analogues: synthesis of novel pyrimidine thioglycosides as antiviral agents against SARS-COV-2 and avian influenza H5N1 viruses. ACS omega. 2021;6(26):16890–16904.
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
   PubMed Web of Science ®Google Scholar
• V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–170.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus isolated from patients with pneumonia in China in 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol. 2000;81(4):853–879.
   PubMedGoogle Scholar
• Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG, Ding J. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res. 2003;31:7117–7130.
   PubMed Web of Science ®Google Scholar
• Eckerle LD, Becker MM, Halpin RA, et al. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathogens. 2010;6(5):e1000896.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B. 1.351 and B. 1.1. 248: escape from therapeutic antibodies and antibodies induced by infection and vaccination. BioRxiv. 2021;2021–2022.
   Google Scholar
• Wu C-Y, Lin Y-S, Yang YH, Shu LH, Cheng YC, Te Liu H. GB-2 inhibits ACE2 and TMPRSS2 expression: in vivo and in vitro studies. Biomed. Pharmacother. 2020;132:110816.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Dehghan M, Raj JM, et al. Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study. BMJ. 2021;372.
   Google Scholar
• Lu D, Chatterjee S, Xiao K, et al. MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. J Mol Cell Cardiol. 2020;148:46–49.
   PubMed Web of Science ®Google Scholar
• Van de Leemput J, Han Z. Understanding individual SARS-CoV-2 proteins for targeted drug development against COVID-19. Mol Cell Biol. 2021.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:6492.
   Web of Science ®Google Scholar
• Tvarogová J, Madhugiri R, Bylapudi G, Ferguson LJ, Karl N, Ziebuhr J. Identification and characterization of a human coronavirus 229E nonstructural protein 8-associated RNA 3′-terminal adenylyltransferase activity. J Virol. 2019;93(12):10–1128.
   Web of Science ®Google Scholar
• Dai W, Zhang B, Jiang XM, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331–1335.
   PubMed Web of Science ®Google Scholar
• Hilgenfeld R. From SARS to MERS: crystallographic studies of coronaviral proteases from SARS to MERS have enabled antiviral drug design. FEBS J. 2014;281(18):4085–4096.
   PubMed Web of Science ®Google Scholar
• MacDonald EA, Frey G, Namchuk MN, Harrison SC, Hinshaw SM, Windsor IW. Recognition of divergent viral substrates by the SARS-CoV-2 main protease. ACS Infect. Dis. 2021;7(9):2591–2595.
   PubMed Web of Science ®Google Scholar
• Verma N, Henderson JA, Shen J. Proton-coupled conformational activation of SARS coronavirus main proteases and opportunity for designing small-molecule broad-40 spectrum targeted covalent inhibitors. J Am Chem Soc. 2020;142(52):21883–21890.
   PubMed Web of Science ®Google Scholar
• Frecer V, Miertus S. Antiviral agents against COVID-19: structure-based design of specific peptidomimetic inhibitors of SARS-CoV-2 main protease. RSC Adv. 2020;10(66):40244–40263.
   PubMed Web of Science ®Google Scholar
• Zhang C-H, Spasov KA, Reilly RA, et al. Optimization of triarylpyridinone inhibitors of the main protease of SARS-CoV-2 to low -nanomolar antiviral potency. ACS Med Chem Lett. 2021;12(8):1325–1332.
   PubMed Web of Science ®Google Scholar
• Thanigaimalai P, Konno S, Yamamoto T, et al. Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies. Eur. J. Med. Chem. 2013;68:372–384.
   PubMed Web of Science ®Google Scholar
• Sohrabi C, Alsafi Z, O’Neill N, et al. Corrigendum to World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surgery. 2020;77:217.
   PubMed Web of Science ®Google Scholar
• Tobaiqy M, Qashqary M, Al-Dahery S. Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020;2(3):100061.
   PubMedGoogle Scholar
• Yang J, Lin X, Xing N, Zhang H, Wu H, Xue W. Structure-based discovery of novel non-peptide inhibitors targeting SARS-CoV-2 Mpro. J Chem Inf Model. 2021;61(8):3917–3926.
   PubMed Web of Science ®Google Scholar
• Gatti M, De Ponti F. Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities. Pharmaceutics. 2021;13(3):302.
   PubMed Web of Science ®Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
   PubMed Web of Science ®Google Scholar
• Lim J, Jeon S, Shin HY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35:e79–e79.
   PubMed Web of Science ®Google Scholar
• Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinl Infect Dis. 2020;71(15):732–739.
   PubMed Web of Science ®Google Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel Investigational Anti-SARS-CoV-2 Agent Ensitrelvir “S-217622”: a Very Promising Potential Universal Broad-Spectrum Antiviral at the Therapeutic Frontline of Coronavirus Species. ACS Omega. 2023;8(6):5234–5246.
   PubMedGoogle Scholar
• Rabie AM. Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication. ACS Omega. 2022;7(3):2960–2969.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease. ACS Omega. 2022;7(25):21385–21396.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Teriflunomide: a possible effective drug for the comprehensive treatment of COVID-19. Curr Res Pharmacol Drug Discovery. 2021;2:100055.
   PubMedGoogle Scholar
• Rabie AM, Abdalla M. Forodesine and Riboprine Exhibit Strong Anti-SARS-CoV-2 Repurposing Potential: in silico and In Vitro Studies. ACS Bio Med Chem. 2022;2(6):565–585.
   PubMedGoogle Scholar
• Rabie AM. New potential inhibitors of coronaviral main protease (CoV-Mpro): strychnine bush, pineapple, and ginger could be natural enemies of COVID-19. Int J New Chem. 2022;9(3):225–237.
   Google Scholar
• Rafiq A, Jabeen T, Aslam S, et al. A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products. Molecules. 2023;28(12):4860.
   PubMed Web of Science ®Google Scholar
• Esharkawy ER, Almalki F, Hadda TB. In vitro potential antiviral SARS-CoV-19-activity of natural product thymohydroquinone and dithymoquinone from Nigella sativa. Bioorg. Chem. 2022;120:105587.
   PubMed Web of Science ®Google Scholar
• Dyer O. Covid-19: remdesivir Has Little or No Impact on Survival. WHO Trial Shows. 2020.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;383(19):1813–1836.
   PubMed Web of Science ®Google Scholar
• Zhou S, Hill CS, Sarkar S, et al. β-D-N 4- hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021;224(3):415–419.
   PubMed Web of Science ®Google Scholar
• Salganik RI, Vasjunina EA, Poslovina AS, Andreeva IS. Mutagenic action of N4-hydroxycytidine on Escherichia coli B cyt-. Mutat Res. 1973;20(1):1–5.
   PubMedGoogle Scholar
• Janion C, Glickman BW. N4-hydroxycytidine: a mutagen specific for AT to GC transitions. Mutat Res. 1980;72(1):43–47.
   PubMedGoogle Scholar
• Konno S, Kobayashi K, Senda M, et al. 3CL protease inhibitors with an electrophilic arylketone moiety as anti-SARS-CoV-2 agents. J Med Chem. 2021;65(4):2926–2939.
   PubMed Web of Science ®Google Scholar
• Chia CB. Novel nitrile peptidomimetics for treating COVID-19 treatment. ACS Med Chem Lett. 2022;13(3):330–331.
   PubMedGoogle Scholar
• Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–293.
   PubMed Web of Science ®Google Scholar
• Liu F, Han K, Blair R, et al. SARS-CoV-2 infects endothelial cells in vivo and in vitro. Front Cell Infect Microbiol. 2021;11:701278.
   PubMed Web of Science ®Google Scholar
• Barakat A, Mostafa A, Ali M, et al. Design, synthesis and in vitro evaluation of the spirooxindole-based phenylsulfonyl moiety as a candidate anti-SAR-CoV-2 and MERS-CoV-2 agent with the implementation of combination studies. Int J Mol Sci. 2022;23(19):11861.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Miyagi S, Yoshida Y, et al. Synthesis and biological evaluation of umifenovir analogues as Anti-SARS-CoV-2 Agents. ChemistrySelect. 2022;7(30):e202202097.
   PubMed Web of Science ®Google Scholar
• Srour AM, Panda SS, Mostafa A, et al. Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. Bioorg. Chem. 2021;117:105466.
   PubMed Web of Science ®Google Scholar
• Seliem IA, Girgis AS, Moatasim Y, et al. New Pyrazine Conjugates: synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2. ChemMedChem. 2021;16(22):3418–3427.
   PubMed Web of Science ®Google Scholar
• Rabie AM. Improved synthesis of the anti-SARS-CoV-2 investigational agent (E)-N-(4-cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (cyanorona-20). Rev Chim. 2022;73(4):69–75.
   Google Scholar
• Ghosh AK, Raghavaiah J, Shahabi D, et al. Indole chloropyridinyl ester-derived SARS-CoV-2 3CLpro inhibitors: enzyme inhibition, antiviral efficacy, structure–activity relationship, and X-ray structural studies. J Med Chem. 2021;64(19):14702–14714.
   PubMed Web of Science ®Google Scholar
• Fomenko VV, Rudometova NB, Rogachev AD, Fando AA, Zaykovskaya AV, Salakhutdinov NF. Synthesis and in vitro study of antiviral activity of glycyrrhizin nicotinate derivatives against HIV-1 pseudoviruses and SARS-CoV-2 viruses. Molecules. 2022;27(1):295.
   PubMed Web of Science ®Google Scholar
• Abu-Zaied MA, Elgemeie GH, Halaweish FT, Hammad SF. Synthesis of novel pyridine and pyrimidine thioglycoside phosphoramidates for the treatment of COVID-19 and influenza A viruses. Nucleosides Nucleotides Nucleic Acids. 2022;41(9):851–877.
   PubMed Web of Science ®Google Scholar
• Al-Harbi SA. Synthesis and characterization of violurate-based Mn (II) and Cu (II) complexes nano-crystallites as DNA-binders and therapeutics agents against SARS-CoV-2 virus. J Saudi Chem Soc. 2022;26(5):101528.
   Web of Science ®Google Scholar
• Nishiuchi K, Ohashi H, Nishioka K, et al. Synthesis and antiviral activities of neoechinulin B and its derivatives. J Natural Prod. 2021;85(1):284–291.
   PubMed Web of Science ®Google Scholar
• Guo Y, Meng J-R, Liu J-Z, et al. Synthesis and biological evaluation of honokiol derivatives bearing 3-((5-phenyl-1, 3, 4-oxadiazol-2-yl) methyl)oxazol-2(3H)-ones as potential viral entry inhibitors against SARS-CoV-2. Pharmaceuticals. 2021;14(9):885.
   Web of Science ®Google Scholar
• Lee JY, Shin YS, Jeon S, et al. Synthesis and biological evaluation of 2-benzylaminoquinazolin-4 (3 H)-one derivatives as a potential treatment for SARS-CoV-2 infection. Bull. Korean Chem. Soc. 2022;43(3):412–416.
   PubMed Web of Science ®Google Scholar
• Shin YS, Lee JY, Jeon S, et al. Optimization of 2-Aminoquinazolin-4-(3H)-one Derivatives as Potent Inhibitors of SARS-CoV-2: improved Synthesis and Pharmacokinetic Properties. Pharmaceuticals. 2022;15(7):831.
   Web of Science ®Google Scholar
• Guevara-Pulido J, Jiménez RA, Morantes SJ, Jaramillo DN, Acosta‐Guzmán P. Design, Synthesis, and Development of 4-[(7-Chloroquinoline-4-yl) amino] phenol as a Potential SARS-CoV-2 Mpro Inhibitor. ChemistrySelect. 2022;7(15):e202200125.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang Y, Wang M, et al. Quinoline and quinazoline derivatives inhibit viral RNA synthesis by SARS-CoV-2 RdRp. ACS Infect. Dis. 2021;7(6):1535–1544.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen K, Zhang Z, et al. Investigating derivatives of tanshinone IIA sulfonate sodium and chloroxine for their inhibition activities against the SARS-CoV-2 papain-like protease. ACS omega. 2022;7(51):48416–48426.
   PubMed Web of Science ®Google Scholar
• Herrmann L, Yaremenko IA, Çapcı A, et al. Synthesis and in vitro study of artemisinin/synthetic peroxide-based hybrid compounds against SARS-CoV-2 and cancer cells. ChemMedChem. 2022;17(9):e202200005.
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdel-Dayem MA, Abdalla M. Promising Experimental Anti-SARS-CoV-2 Agent “SLL-0197800”: the Prospective Universal Inhibitory Properties against the Coming Versions of the Coronavirus. ACS Omega. 2023;8(39):35538–35554.
   PubMed Web of Science ®Google Scholar
• Wang X, Burdzhiev NT, Hu H, et al. Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection In Vitro. Viruses. 2023;15(2):502.
   PubMed Web of Science ®Google Scholar
• Wu J, Feng B, Gao L-X, et al. Synthesis and Biochemical Evaluation of eight H-indeno [1,2-d] thiazole Derivatives as Novel SARS-CoV-2 3CL Protease Inhibitors. Molecules. 2022;27(10):3359.
   PubMed Web of Science ®Google Scholar
• Pohl MO, Martin-Sancho L, Ratnayake R, et al. Sec61 inhibitor apratoxin S4 potently inhibits SARS-CoV-2 and exhibits broad-spectrum antiviral activity. ACS Infect. Dis. 2022;8(7):1265–1279.
   PubMed Web of Science ®Google Scholar
• Chemboli R, Kapavarapu R, Deepti K, et al. Pyrrolo[2,3-b] quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico/in vitro assessment. J Mol Struct. 2021;1230:129868.
   PubMed Web of Science ®Google Scholar
• Shcherbakov D, Baev D, Kalinin MM, et al. Design and evaluation of bispidine-based SARS-CoV-2 main protease inhibitors. ACS Med Chem Lett. 2021;13(1):140–147.
   PubMed Web of Science ®Google Scholar
• Wansri R, Lin ACK, Pengon J, et al. Semi-synthesis of N-aryl amide analogs of piperine from Piper nigrum and evaluation of their antitrypanosomal, antimalarial, and anti-SARS-CoV-2 main protease activities. Molecules. 2022;27(9):2841.
   PubMed Web of Science ®Google Scholar
• Mohamed NM, Eltelbany RF. Synthetic coumarin derivatives as SARS-CoV-2 major protease inhibitors: design, synthesis, bioevaluation and molecular docking. ChemistrySelect. 2021;6(47):13616–13626.
   Web of Science ®Google Scholar
• Rabie AM, Eltayb WA. Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: a Promising In Silico/In vitro Repositioning Research Study. Mol Biotechnol. 2023;1–20.
   Web of Science ®Google Scholar
• Venkateshan M, Muthu M, Suresh J, Kumar RR. Azafluorene derivatives as inhibitors of SARS CoV-2 RdRp: synthesis, physicochemical, quantum chemical, modeling and molecular docking analysis. J Mol Struct. 2020;1220:128741.
   PubMed Web of Science ®Google Scholar
• Belhassan A, En-Nahli F, Zaki H, Lakhlifi T, Bouachrine M. Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. Life Sci. 2020;262:118469.
   PubMed Web of Science ®Google Scholar
• Mudi PK, Mahato RK, Verma H, et al. In silico anti-SARS-CoV-2 activities of five-membered heterocycle-substituted benzimidazoles. J Mol Struct. 2022;1261:132869.
   PubMed Web of Science ®Google Scholar
• Algethami FK, Cherif M, Jlizi S, et al. Design, microwave-assisted synthesis and in silico prediction study of novel isoxazole-linked pyranopyrimidinone conjugates as new targets for searching potential Anti-SARS-CoV-2 agents. Molecules. 2021;26(20):6103.
   PubMed Web of Science ®Google Scholar
• Gatfaoui S, Sagaama A, Issaoui N, Roisnel T, Marouani H. Synthesis, experimental, theoretical study and molecular docking of 1-ethylpiperazine-1, 4-diium bis (nitrate). Solid State Sci. 2020;106:106326.
   Web of Science ®Google Scholar
• Anthony LA, Rajaraman D, Sundararajan G, et al. Synthesis, crystal structure, Hirshfeld surface analysis, DFT, molecular docking and molecular dynamic simulation studies of (E)-2, 6-bis (4-chlorophenyl)-3-methyl-4-(2-(2, 4, 6-trichlorophenyl) hydrazono) piperidine derivatives. J Mol Struct. 2022;1266:133483.
   PubMed Web of Science ®Google Scholar
• Gupta A, Iqbal S, Roohi MK, Zaheer MR, Shankar K. Visible light-promoted green and sustainable approach for one-pot Synthesis of 4, 4’-(arylmethylene) bis (1H-pyrazol-5-ols), In Vitro Anticancer Activity, and Molecular Docking with Covid-19 Mpro. ACS omega. 2022;7(38):34583–34598.
   PubMedGoogle Scholar
• Addoum B, El Khalfi B, Sakoui S, Derdak R, Elmakssoudi A, Soukri A. Synthesis and molecular docking studies of some pyrano [2,3-c] pyrazole as an Inhibitor of SARS-Coronavirus 3CL protease. Lett Appl NanoBioscience. 2022;11:3780.
   Google Scholar
• Masaret GS. Synthesis of new spiropyrazole derivatives under microwaves irradiation and docking study for inhibition the microbes and COVID-19. J Mol Struct. 2022;1269:133581.
   PubMed Web of Science ®Google Scholar
• Mohamed GG, Omar MM, Ahmed YM. Metal complexes of Tridentate Schiff bases: synthesis, characterization, biological activity, and molecular docking studies with COVID-19 protein receptors. Z Anorg Allg Chem. 2021;647(23–24).
   PubMed Web of Science ®Google Scholar
• Jayabal K, Elumalai D, Leelakrishnan S, et al. Green and regioselective approach for the synthesis of 3-substituted indole based 1, 2-dihydropyridine and azaxanthone derivatives as a potential lead for SARS-CoV-2 and delta plus mutant virus: DFT and docking studies. ACS omega. 2022;7(48):43856–43876.
   PubMed Web of Science ®Google Scholar
• Tarika JD, Dexlin XD, Madhankumar S, Ayanthi DD, Beaula TJ. Tuning the computational evaluation of spectroscopic, ELF, LOL, and NCI analysis and molecular docking of the novel anti COVID-19 molecule 4-dimethylamino pyridinium 3, 5-dichlorosalicylate. Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy. 2021;259:119907.
   PubMed Web of Science ®Google Scholar
• Topal T, Zorlu Y, Karapınar N. Synthesis, X-ray crystal structure, IR and Raman spectroscopic analysis, quantum chemical computational and molecular docking studies on hydrazone-pyridine compound: as an insight into the inhibitor capacity of main protease of SARS-CoV2. J Mol Struct. 2021;1239:130514.
   PubMed Web of Science ®Google Scholar
• Nesaragi AR, Kamble RR, Hoolageri SR, Mavazzan A, Madar SF, Anand A. WELPSA: a natural catalyst of alkali and alkaline earth metals for the facile synthesis of tetrahydrobenzo [b] pyrans and pyrano [2,3-d] pyrimidinones as inhibitors of SARS-CoV-2. Appl. Organomet. Chem. 2022;36(1):e6469.
   PubMed Web of Science ®Google Scholar
• Muhammad ZA, Farghaly TA, Althagafi I, Al‐Hussain SA, Zaki ME, Harras MF. Synthesis of antimicrobial azoloazines and molecular docking for inhibiting COVID-19. J Heterocycl Chem. 2021;58(6):1286–1301.
   PubMed Web of Science ®Google Scholar
• Qureshi F, Nawaz M, Hisaindee S, et al. Microwave assisted synthesis of 2-amino-4-chloro-pyrimidine derivatives: anticancer and computational study on potential inhibitory action against COVID-19. Arabian J. Chem. 2022;15(12):104366.
   PubMed Web of Science ®Google Scholar
• Alshammari MB, Ramadan M, Aly AA, et al. Synthesis of potentially new schiff bases of N-substituted-2-quinolonylacetohydrazides as anti-COVID-19 agents. J Mol Struct. 2021;1230:129649.
   PubMed Web of Science ®Google Scholar
• Divya KM, Savitha DP, Krishna GA, Dhanya TM, Mohanan PV. Crystal structure, DFT studies, Hirshfeld surface and energy framework analysis of 4-(5-nitro-thiophen-2-yl)-pyrrolo[1,2-a] quinoxaline: a potential SARS-CoV-2 main protease inhibitor. J Mol Struct. 2022;1251:131932.
   PubMed Web of Science ®Google Scholar
• Rashdan HR, Abdelmonsef AH, Abou-Krisha MM, Yousef TA. Synthesis and identification of novel potential thiadiazole based molecules containing 1, 2, 3-triazole moiety against COVID-19 main protease through structure-guided virtual screening approach. Appl Biochem Biotechnol. 2021;193:3602–3623.
   PubMedGoogle Scholar
• Rashdan HR, Abdelmonsef AH. In silico study to identify novel potential thiadiazole-based molecules as anti-Covid-19 candidates by hierarchical virtual screening and molecular dynamics simulations. Struct Chem. 2022;33(5):1727–1739.
   PubMed Web of Science ®Google Scholar
• Al-Janabi AS, Elzupir AO, Yousef TA. Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases. J Mol Struct. 2021;1228:129454.
   PubMed Web of Science ®Google Scholar
• Alghamdi A, Abouzied AS, Alamri A, et al. Synthesis, molecular docking, and dynamic simulation targeting main protease (Mpro) of new, Thiazole clubbed pyridine scaffolds as potential COVID-19 inhibitors. Curr Issues Mol Biol. 2023;45(2):1422–1442.
   PubMed Web of Science ®Google Scholar
• Aouad MR, Khan DJ, Said MA, et al. Novel 1, 2, 3-triazole derivatives as potential Inhibitors against Covid-19 Main Protease: synthesis, characterization, molecular docking and DFT studies. ChemistrySelect. 2021;6(14):3468–3486.
   PubMed Web of Science ®Google Scholar
• Singh G, Saini A, Kaur A. Design of new bis-triazolyl structure for identification of inhibitory activity on COVID-19 main protease by molecular docking approach. J Mol Struct. 2022;1250:131858.
   PubMed Web of Science ®Google Scholar
• Hussein RK, Elkhair HM. Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19. J Mol Struct. 2021;1231:129979.
   PubMed Web of Science ®Google Scholar
• Gorai S, Junghare V, Kundu K, et al. Synthesis of dihydrobenzofuro [3, 2-b]chromenes as potential 3CLpro inhibitors of SARS-CoV-2: a molecular docking and molecular dynamics study. ChemMedChem. 2022;17(8):e202100782.
   PubMed Web of Science ®Google Scholar
• Mary SJ, Pradhan S, James C. Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT–IR, FT–Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl) methylidene]-hydrazinecarbothioamide (dimer)-quantum chemical approach. Spectrochimica Acta, Part A: Molecular and Biomolecular Spectroscopy. 2021;251:119388.
   PubMed Web of Science ®Google Scholar
• Mun CS, Hui LY, Sing LC, Karunakaran R, Ravichandran V. Multi-targeted molecular docking, pharmacokinetics, and drug-likeness evaluation of coumarin-based compounds targeting proteins involved in development of COVID-19. Saudi J Biol Sci. 2022;29(12):103458.
   PubMed Web of Science ®Google Scholar
• Chidambaram S, El-Sheikh MA, Alfarhan AH, Radhakrishnan S, Akbar I. Synthesis of novel coumarin analogues: investigation of molecular docking interaction of SARS-CoV-2 proteins with natural and synthetic coumarin analogues and their pharmacokinetics studies. Saudi J Biol Sci. 2021;28(1):1100–1108.
   PubMed Web of Science ®Google Scholar